Aim of the research: generalization and optimization of methods of treatment of patient’s with fibrohistiocytic tumor of soft tissues.

Materials and methods: There were 79 (100%) patients under observation with malignant fibrohistiocytic tumor of soft tissue in the period from 2000 to 2006 year. There were 41 (51,9%) male and 38 (48,1%) female patients. The average age of patients were 45,5. Depending on localization of tumor on the lower extremities 47 (59,4%), on the upper extremities 19 (24%), trunk 13 (16,5%) of patients. Depending on histological structure of tumor the patients were distributed in the following way: 69 (87,3%) malignant fibrous histiocytoma, 10 (12,6%) atypical fibroxanthoma. In 49 (6,2%) cases were the initial tumor, at 30 (37%) were relapse tumor. In diagnostic used complex methods with including into investigation rentgenography, echography, USM, KT and MRT and morphological methods of research. The main methods of treatment are surgical, combine and complex. In initial and localized processes (the size of tumor < 5 cm) the main method is surgical (wide carving of tumor). The additional treatments to these patients did not make and they released under dynamic control. In our case there were 24 (30,4%) such kind of patients. In size of tumor from 5 to 10cm, and also in relapse at 17 (21,5%) patients on the first stage made surgical intervention, and then got distance gamma therapy (SOD 50Gy). In postoperative period conducted chemotherapy to 6 (7,5%) patients. In size of tumor more than 10cm in localization in upper extremities and trunk at 5(6,3%) patients the treatment begins with RT, and then surgical intervention +PXT by diagram CAPO, MAID, CAV II and others. In localization on lower extremities at 3 (3,8%) patients treatment begins with intra-arterial infusion Doxorubicin hydrochloride in 30mg/m2 during for 3 days (90mg/m2) and then surgical intervention +RT 50 Gy. At 18 (22,8%) patients were carving relapse, at 9 (11,5%) amputation, at 4 (5,1%) patients were exarticulation.

Subclinic liver dysfunctions (SLD) wildly spread among adult oncology patients and can negatively influence to results of some oncology patients treatment. But information concerning same problem in children is remain lack.

The purpose of this investigation was the determination of SLD spreading among children with sarcomas of bone and soft tissues and estimation its clinical significance.

Materials and methods: 200 children with sarcomas of bones and soft tissues were involved in the observation (136 boys and 64 girls) in age groups: 2–10 years – 86 and older 10 years – 114. All children were examined with the help of clinic and laboratory methods including biochemical, serologic and immunologic testing of the blood.

Results and discussion: Results obtained if the investigation demonstrated that different degree of the SLD was widely spread among children with sarcomas – biochemical signs of SLD were detected at 26.0% children. Frequency and degree of severity of SLD increased parallel with increasing the clinical stages of sarcomas.

Serological markers of infections caused hepatitis B and C viruses in all children had biochemical signs of SLD were detected in several times frequently than in all children had no above mentioned signs of subclinic hepatopathy.

Presence of SLD signs in children with sarcomas was accompanied with more expressed depression of immunologic reactivity including natural antitumor resistance estimated on the base of natural killer cells’ cytotoxicity.

Besides, presence of biochemical signs of SLD in children with sarcomas was accompanied with more frequent and expressed side-effects of chemotherapy and lower effect of treatment of those children.

Conclusions: 1. SLD spread among children with sarcoma as like as among adult oncology patients. 2. Presence of SLD children with sarcomas has important clinical significance.